Sotrastaurin acetate

Overview

Sotrastaurin (AEB071) acetate is a selective, orally active PKC inhibitor. Sotrastaurin acetate inactivates NF-κB by inhibiting PKC α, β, θ, γ subtypes, thereby reducing the transcription levels of immune response-related genes. Sotrastaurin acetate effectively inhibits alloreactive T cell proliferation, conventional T cell activation, as well as the production of pro-inflammatory cytokines and B lymphocytes. Sotrastaurin acetate also maintains the functional and phenotypic stability of regulatory T cells, enhances Foxp3 expression and restores the balance of helper T lymphocytes. Sotrastaurin acetate can prolong the survival time of allografts, and alleviate inflammatory responses and myasthenic symptoms by reducing anti- AChR antibody levels. Sotrastaurin acetate is widely used in studies related to kidney transplantation, psoriasis and myasthenia gravis.

Application

Products | Products > Disease Areas > Myasthenia gravis | Products > Disease Areas > Psoriasis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Skin Inflammation | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > NF-κB | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > PKC | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-10540
• CAS No.: 908351-31-5
• Molecular Formula: C27H26N6O4
• Molecular Weight: 498.53
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source